Physician profile
Arthur A Kornbluth
NPI 1104835784
$1,885,717.21
in general payments reported to CMS, 2019-2025
38 companies · $293K in 2025
The $293K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250K · 2020: $174K · 2021: $239K · 2022: $342K · 2023: $231K · 2024: $356K · 2025: $293K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $703K · Travel and Lodging: $86K · Consulting Fee: $54K · Food and Beverage: $28K · Honoraria: $8,456 · Education: $16.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $703,385.77 |
| Travel and Lodging | $86,369.50 |
| Consulting Fee | $54,227.94 |
| Food and Beverage | $28,218.14 |
| Honoraria | $8,455.63 |
| Education | $16.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447,136.78 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $308,636.79 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $281,262.49 | 2019-2025 | Tremfya, Stelara |
| Janssen Scientific Affairs, LLC | $262,296.86 | 2019-2025 | Tremfya |
| Pfizer INC. | $227,809.40 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116,147.97 | 2019-2025 | Entyvio, Gattex |
| Lilly USA, LLC | $104,663.98 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $67,760.28 | 2024-2025 | Zymfentra, Vegzelma |
| Amgen INC. | $40,809.59 | 2020-2023 | Amjevita, Avsola |
| Celgene Corporation | $11,266.06 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $11,243.25 | 2019-2024 | Dificid, Zerbaxa, Recarbrio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,371.46 | 2019-2025 | Xifaxan, Trulance |
| Qol Medical, LLC | $758.17 | 2019-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $640.00 | 2020 | |
| Ucb, INC. | $437.63 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $300.36 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $286.90 | 2020-2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.97 | 2023-2024 | Cyltezo |
| Allergan, INC. | $175.69 | 2019 | |
| Organon LLC | $166.84 | 2021-2025 | Hadlima |
| Ironwood Pharmaceuticals, INC | $155.25 | 2019-2021 | |
| Shire North American Group INC | $137.86 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $125.97 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $120.26 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $116.43 | 2023-2025 | Cologuard Collection Kit |
| Endo Pharmaceuticals INC. | $102.60 | 2019-2020 | |
| Ardelyx, INC. | $97.34 | 2024-2025 | Ibsrela |
| Sandoz INC. | $93.71 | 2024-2025 | Hyrimoz |
| Nestle Healthcare Nutrition INC. | $72.14 | 2020-2023 | |
| Aimmune Therapeutics, INC. | $52.04 | 2025 | Vowst |
| Braintree Laboratories, INC. | $48.25 | 2019-2023 | Sutab, Suflave |
| Vivus LLC | $44.10 | 2024-2025 | Qsymia |
| Boston Scientific Corporation | $42.60 | 2022 | |
| Romark Laboratories, Lc | $41.75 | 2019 | |
| Glaxosmithkline, LLC. | $34.19 | 2019-2024 | Trelegy Ellipta |
| Fresenius Kabi USA, LLC | $22.05 | 2023 | |
| Novo Nordisk INC | $20.90 | 2025 | Wegovy |
| Redhill Biopharma INC. | $17.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Kornbluth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.